70060-12-7

Usage

Uses

Used in Pharmaceutical Synthesis:
5-FLUOROBENZO[B]THIOPHENE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 5-FLUOROBENZO[B]THIOPHENE is utilized as a building block for the creation of novel agrochemicals, contributing to the development of more effective and targeted pest control agents.
Used in Material Science:
5-FLUOROBENZO[B]THIOPHENE is employed in material science for the development of advanced materials with specific properties, such as improved conductivity or stability, due to its unique molecular structure.
Used in Organic Electronics:
In the field of organic electronics, 5-FLUOROBENZO[B]THIOPHENE is used as a component in the design and fabrication of organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic photovoltaics, owing to its electronic properties.
Used in Medicinal Chemistry Research:
5-FLUOROBENZO[B]THIOPHENE is studied for its biological activity and potential pharmacological properties, making it a valuable compound in the discovery and development of new therapeutic agents.
It is crucial to handle 5-FLUOROBENZO[B]THIOPHENE with care, as it may present health and environmental risks if not managed properly.

Upstream product

• 352-33-0 1-Chloro-4-fluorobenzene 
• 874357-16-1 (4-fluorophenylthio)-acetaldehyde dimethyl acetal 
• 13771-69-2 ethyl 5-fluorobenzo[b]thiophene-2-carboxylate 
• 154630-32-7 methyl 5-fluorobenzo[b]thiophene-2-carboxylate 
• 371-42-6 4-Fluorothiophenol 
• 2646-90-4 2,5-difluorobenzaldehyde 
• 70060-13-8 5-fluorobenzo[b]thiophene-2-carboxylic acid 
• 153687-44-6 (2,2-diethoxyethyl)(4-fluorophenyl)sulfane 

Downstream Products

• 732223-07-3 2-amino-5-fluorobenzothiophene 
• 118575-04-5 O-Benzyl-N-[1-(5-fluoro-benzo[b]thiophen-2-yl)-ethyl]-hydroxylamine 
• 344764-43-8 3-chloro-1-(5-fluorobenzo[b]thiophen-3-yl)propan-1-one 
• 346592-33-4 4-(5-fluoro-benzo[b]thiophen-2-yl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 346592-35-6 4-(5-fluoro-benzo[b]thiophen-2-yl)-4-hydroxy-2-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 212078-65-4 1-(5-fluorobenzo[b]thiophen-2-yl)-3-(1-triphenylmethyl-1H-imidazol-4-yl)-propan-1-ol 
• 698366-78-8 (E)-3-(5-fluorobenzo[b]thiophen-2-yl)-2-propen-1-ol 
• 698366-58-4 ethyl (E)-3-(5-fluorobenzo[b]thiophen-2-yl)-2-propenoate 
• 698367-59-8 1-(5-fluorobenzo[b]thiophen-2-yl)-3-(1H-imidazol-4-yl)-propan-1-ol 
• 153687-47-9 ethyl 1,4-dihydro-4-oxo-6-fluorobenzothieno<2,3-b>pyridine-3-catboxylate 
• 153687-48-0 ethyl 1-ethyl-1,4-dihydro-4-oxo-6-fluorobenzothieno<2,3-b>pyridine-3-catboxylate 
• 153687-46-8 2-bisethoxycarbonylvinylamino-5-fluorobenzothiophene 
• 310466-60-5 2-bromo-1-(5-fluorobenzo[b]thiophen-2-yl)propan-1-one 
• 263544-05-4 3-(chloromethyl)-5-fluorobenzo[b]-thiophene 

Relevant academic research and scientific papers

Enantioselective hydroarylation or hydroalkenylation of benzo[b]thiophene 1,1-dioxides with organoboranes

An efficient protocol for the asymmetric hydroarylation and hydroalkenylation of benzo[b]thiophene 1,1-dioxides with organoboranes has been developed. The combination of a rhodium(I) precatalyst and a chiral diene ligand constitutes the catalytic system, which enables the facile synthesis of 2,3-dihydrobenzo[b]thiophene 1,1-dioxides in good yields with high enantioselectivities. The merging of this asymmetric hydroarylation with the downstream alkylations delivers 2,3-dihydrobenzo[b]thiophene 1,1-dioxides that contain two continuous quaternary stereocenters with high enantioselectivities in a diastereodivergent manner.

Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands

Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated 18F-fluorination of aryl boron reagents with 18F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of 18F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.

C-benzo five-membered heteroaromatic aryl glucoside derivative as well as preparation method and application thereof

The invention discloses a C-benzo five-membered heteroaromatic aryl glucoside derivative shown in the general formula (I) (in the description), a preparation method of the derivative or an intermediate of the derivative, as well as application of the derivative. In the general formula (I), R, R1, R2, R3, R4, X and Y are defined in the description. The C-benzo five-membered heteroaromatic aryl glucoside derivative is novel in structure, has quite strong inhibitory activity on SGLT-2, has high selection ratio for SGLT-1 and SGLT-2, and can be used for preparing drugs for treating and preventing diseases relevant to SGLT-2.

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES

3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

Indole derivatives for the treatment of depression and anxiety

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Design and Synthesis of a Fluoroindolocarbazole Series as Selective Topoisomerase I Active Agents. Discovery of Water-Soluble 3,9-Difluoro-12,13-dihydro-13-[6-amino-β-D-glucopyranosyll]-5H,13H-benzo[b] -thienyl[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (BMS-251873) with Curative Antitumor Activity against Prostate Carcinoma Xenograft Tumor Model

A series of fluoroindolocarbazoles were studied with respect to their topoisomerase I activity, cytotoxicity, selectivity, and in vivo antitumor activity. Emerging from this series was BMS-251873, a potential clinical candidate possessing a robust pharmacological profile including curative antitumor activity against prostate carcinoma.

C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors.

Novel nonsteroidal C(17,20)-lyase inhibitors were synthesized using de novo design based on its substrate, 17 alpha-hydroxypregnenolone, and several compounds exhibited potent C(17,20)-lyase inhibition. However, in vivo activities were found to be short-lasting, and in order to improve the duration of action, a series of benzothiophene derivatives were evaluated. As a result, compounds 9h, (S)-9i, and 9k with nanomolar enzyme inhibition (IC(50)=4-9 nM) and 9e (IC(50)=27 nM) were identified to have powerful in vivo efficacy with extended duration of action. The key structural determinants for the in vivo efficacy were demonstrated to be the 5-fluoro group on the benzothiophene ring and the 4-imidazolyl moiety. Superimposition of 9k and 17 alpha-hydroxypregnenolone demonstrated their structural similarity and enabled rationalization of the pharmacological results. In addition, selected compounds were also identified to be potent inhibitors of human enzyme with IC(50) values of 20-30 nM.